Using DNA nanostructures to improve drug delivery and biosensing
Programmable DNA Nanostructures as Biomedical and Structural Scaffolds
['FUNDING_OTHER'] · STATE UNIVERSITY OF NEW YORK AT ALBANY · NIH-11100100
This study is exploring new ways to use tiny DNA structures to deliver medicines more effectively for people with myotonic dystrophy type 1, aiming to improve treatment options and make therapies work better for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NEW YORK AT ALBANY (nih funded) |
| Locations | 1 site (ALBANY, UNITED STATES) |
| Trial ID | NIH-11100100 on ClinicalTrials.gov |
What this research studies
This research focuses on developing programmable DNA nanostructures that can precisely position molecules like antibodies and drugs for various biomedical applications. The team aims to create a robust drug delivery system specifically designed to treat multisystemic diseases, using myotonic dystrophy type 1 as a model. Additionally, they will design 3D DNA crystals to aid in the structural determination of these nanostructures, enhancing our understanding of their interactions in biological systems. Patients may benefit from improved drug delivery methods and better-targeted therapies as a result of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myotonic dystrophy type 1 or other multisystemic diseases requiring advanced drug delivery solutions.
Not a fit: Patients with conditions unrelated to drug delivery or those not affected by multisystemic diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with complex diseases.
How similar studies have performed: Previous research in DNA nanotechnology has shown promise in drug delivery and biosensing, indicating potential for success in this novel application.
Where this research is happening
ALBANY, UNITED STATES
- STATE UNIVERSITY OF NEW YORK AT ALBANY — ALBANY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANDRASEKARAN, ARUN RICHARD — STATE UNIVERSITY OF NEW YORK AT ALBANY
- Study coordinator: CHANDRASEKARAN, ARUN RICHARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.